Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
Dept. of Physics, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. Electronic address: annemieke.wamel@ntnu.no.
Annemieke
A
van Wamel
Phoenix Solutions AS, Oslo, Norway.
Per Christian
PC
Sontum
Phoenix Solutions AS, Oslo, Norway.
Andrew
A
Healey
Phoenix Solutions AS, Oslo, Norway.
Svein
S
Kvåle
Joint Dept. of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Nigel
N
Bush
Joint Dept. of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Jeffrey
J
Bamber
Dept. of Physics, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Catharina
C
de Lange Davies
D000068196:Albumin-Bound Paclitaxel / Q000008:administration & dosage*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D065546:Drug Liberation; D006801:Humans; D008297:Male; D051379:Mice; D017239:Paclitaxel / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D000069453:Ultrasonic Waves
D000068196:Albumin-Bound Paclitaxel; D017239:Paclitaxel
Abraxane®; Acoustic cluster therapy; Act; PC-3 prostate adenocarcinoma; Paclitaxel; Pre-clinical; Targeted drug delivery